HomeIOVA • NASDAQ
add
Iovance Biotherapeutics Inc
Previous close
$10.44
Day range
$10.58 - $11.20
Year range
$3.76 - $18.33
Market cap
3.40B USD
Avg Volume
4.52M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | 31.11M | 12,969.75% |
Operating expense | 101.65M | -6.12% |
Net income | -97.10M | 8.85% |
Net profit margin | -312.16 | 99.30% |
Earnings per share | -0.34 | 27.66% |
EBITDA | -93.44M | 11.19% |
Effective tax rate | 1.48% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 412.54M | 64.43% |
Total assets | 964.32M | 27.34% |
Total liabilities | 195.78M | 9.54% |
Total equity | 768.54M | — |
Shares outstanding | 303.51M | — |
Price to book | 4.03 | — |
Return on assets | -27.78% | — |
Return on capital | -31.56% | — |
Cash Flow
Net change in cash
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Net income | -97.10M | 8.85% |
Cash from operations | -98.43M | -4.77% |
Cash from investing | 40.22M | 125.65% |
Cash from financing | 152.82M | 14,809.76% |
Net change in cash | 94.49M | 137.28% |
Free cash flow | -53.12M | 15.85% |
About
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte therapies against cancer. Wikipedia
Founded
2007
Headquarters
Website
Employees
557